1.  Receptors are mostly membrane-bound proteins that selectively bind small molecules called ligands which results in physiological response.  They are difficult to isolate because they exist in tiny amount and if isolated it will be difficult to purify.

2.  The driving force for drug-receptor interaction is the low energy state of the drug-receptor complex.  The biological activity is related to the drug affinity for the receptor, i.e the stability of the complex.  Dissociation constant of the drug-receptor complex gives an idea a bout how potent is the drug

3.  Includes:

4.  Strong, irreversible bonds (-40 to -110 Kcal/mol stability).  Rarely seen in drug-receptor interaction.  More prevalent in drug-enzyme and drug- DNA interaction.

5.  This type of bond is weaker than covalent bond (-5 Kcal/mol).  At the same time, it is one of the most prevalent bonds in drug-receptor interaction.  The drug molecule must have opposite charge compared to the ionized amino acids found in the receptor or enzyme.  Extent of ionization affects the occurrence of this bond.  The distance between opposite charges has a role as well.

6.  Electronic dipole is formed when we have polarized bond.  In the polarized bond one of the pole will be partially positive and the other partially negative.  These partially positive or negative charges might form an electrostatic bond with either partially charged atoms or ionized elements.

8.  It can be considered as a subtype from dipole- dipole interaction:  X can be N, O or F  Y can be an atom with non-bonded pair of electrons such as N, O and S.  Stability of this bond is -1 to -7 kcal/mol

9.  Of two types:  Intramolecular H-bonding: which occur within the same molecule.  Intermolecular H-bonding: occurs between two nearby molecules

10.  The occurrence of intramolecular H-bonding could affect the pharmacological action of a drug:  P -hydroxybenzoate has more potent antibacterial action compared to methyl salicylate, it is normally used as food additive as preservative.

11.  Occurs between an electron donor group in one molecule and an electron acceptor in another.  Electron donors such as alkenes, alkynes and aromatic ring bearing an electron donating group, and atoms having pairs of non-bonded electrons such as O, N and S  Electron acceptors such as aromatic ring bearing an electron withdrawing group,  These groups might exist in the receptor binding sites:  Electron donor a.a such as tyrosine and carboxylates  Electron acceptor a.a such as cysteine  Having both: such as Histidine, tryptophan and sparagine

13.  Occurs due to temporary non-symmetrical distribution of electron density, this will form temporary dipole that will interact with nearby dipole.  Stability accounts for only -0.5 kcal/mole, this means that this type of bonds are much weaker than other bonds.

14.  Acetylcholine binding to cholinergic receptor as an example.  K d : Is the concentration of drug that produce 50% of maximum activity

15.  The curve describes muscle contraction in smooth muscle upon administering acetylcholine at different concentration.  There is a direct relationship between the level of contraction and Ach concentration  Maximum response will be obtained after reaching the full saturation of receptors  Unknown drugs will be administered to muscle and study the dose-response curve

16.  Full agonist:  Will give the same maximum contraction as Ach.

17.  Partial agonist/ antagonist:  Will give lower level of contraction than Ach.

18.  Antagonist:  Competitive Antagonist  The right shift in response curve means that higher concentration of Acetylcholine is needed (to displace unknown drug from the binding site) to give the same level of activity.

19.  Antagonist:  Non-Competitive Antagonist  Muscle contraction is reduced although Ach concentration is increased.  This means that the unknown inhibits the action of Ach after binding to other binding site …. No + effect will be obtained if we will increase Ach concentration

20.  Agonist agent:  Is compound that will bind to the same binding site as the natural ligand and similarly activate the receptor.  To do so, It must have close similarity in structure to the natural ligand

21.  Antagonist agent:  Is a compound that strongly bind to the receptor,inhibits natural ligand from binding, without activating the receptor  Generally it is bulkier than natural ligand, and will form extra bonds….. Different binding pattern